Streetbeat News

Stock Prices

AVGO

Financial giants have shown a bearish move on Broadcom (NASDAQ:AVGO) with 33 unusual trades. 42% of traders were bearish, while 39% were bullish. The predicted price range for Broadcom is between $66.0 and $180.0 over the next three months. The stock is currently down 1.21% at $149.8, with RSI indicators suggesting it may be oversold. Analysts have set an average price target of $1002.0, with some maintaining high target prices up to $2400.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 3:31 pm

SHYF

The Shyft Group shares are trading higher after DA Davidson upgraded the company from Neutral to Buy and raised their price target to $18.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 3:31 pm

CGTX

Cognition Therapeutics (NASDAQ:CGTX) reported mixed results from its Phase 2 'SHINE' study for Alzheimer's treatment CT1812. While there were trends of cognitive improvement and functional benefits, the drug did not achieve statistical significance on secondary efficacy endpoints. The stock fell 35.10% to $1.54 following the news.

Portfolio Pulse from Vandana Singh

July 29, 2024 | 3:31 pm

AGI

Alamos Gold (NYSE:AGI) has outperformed the market over the past 5 years, delivering an average annual return of 18.32%. A $100 investment in AGI 5 years ago would be worth $231.22 today. The article highlights the impact of compounded returns on investment growth.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 3:31 pm

KEX

Kirby (NYSE:KEX) has outperformed the market over the past 20 years with an average annual return of 9.72%, surpassing the market by 1.33% annually. A $1000 investment in KEX 20 years ago would be worth $6,280.08 today. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 3:30 pm

LIPO

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) shares surged 124% after the company announced the enrollment of the first patients in its Phase 2a clinical trial for LP-310, a treatment for Oral Lichen Planus. The trial is a multi-center, dose-ranging study, and the company is actively screening additional subjects.

Portfolio Pulse from Erica Kollmann

July 29, 2024 | 3:28 pm

BHP

CRIT

HAP

BHP Group Ltd's Escondida mine in Chile faces a potential strike as the union urges its 2,400 members to reject the company's final contract offer. A strike could severely impact copper production and global prices. The union is well-prepared with a significant strike logistics fund and credit agreements. BHP shares are trading lower by 1.14%.

Portfolio Pulse from Shivani Kumaresan

July 29, 2024 | 3:26 pm

SMR

NuScale Power shares are trading lower following a report from Hunterbrook indicating that the company is under SEC investigation.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 3:26 pm

AMC

DIS

AMC Entertainment Holdings Inc (NYSE:AMC) shares are rising after the company reported record-breaking weekend attendance and admissions revenue for 2024. The success was driven by the opening weekend of Walt Disney Co (NYSE:DIS) and Marvel's 'Deadpool & Wolverine,' which set new records for an R-rated film. AMC also saw its highest food and beverage revenue since 2019 and strong merchandise sales.

Portfolio Pulse from Adam Eckert

July 29, 2024 | 3:24 pm

VTVT

The FDA has placed a clinical hold on vTv Therapeutics' (NASDAQ:VTVT) cadisegliatin program, including the ongoing CATT1 Phase 3 trial for type 1 diabetes, due to an unresolved chromatographic signal in a recent study. This has caused VTVT stock to drop by 32.2%.

Portfolio Pulse from Vandana Singh

July 29, 2024 | 3:23 pm